4820 Richard Road SW
Calgary, AB T3E 6L1
Full Time Employees: 19
|Mr. Donald J. McCaffrey||Co-Founder, Chairman, Pres, CEO & Sec.||505.2k||N/A||N/A|
|Mr. Aaron Bradley Cann C.A., CPA, CA, CPA, CBV||Chief Financial Officer||281.8k||N/A||N/A|
|Dr. Ewelina Kulikowski Ph.D.||Chief Scientific Officer||250k||N/A||N/A|
|Dr. Jan O. Johansson M.D., Ph.D.||Sr. VP of Medical Affairs||312.17k||N/A||N/A|
|Dr. Michael Sweeney M.D.||Sr. VP of Clinical Devel.||511.56k||N/A||1961|
|Sarah Zapotichny||Director of Investor Relations & Corp. Communications||N/A||N/A||N/A|
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications. The company was founded in 2001 and is headquartered in Calgary, Canada.
Resverlogix Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.